Journals / Ulusal Travma ve Acil Cerrahi Dergisi / 2019 / Cilt: 25 - Sayı: 2

The therapeutic effects of thalidomide and etanercept on septic rats exposed to lipopolysaccharide

Talidomid ve etanersept’in lipopolisakkarite maruz bırakılan septik sıçanlarda terapötik etkileri

Pages
99–104
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Treatment of septic animals with these agents resulted in a remarkable decrease in the selectedproinflammatory cytokines, angiogenic factors, and reactive oxygen parameters.CONCLUSION: Restoration of cytokine balance and oxidant status to normal levels following treatment with selected therapeuticagents suggests that thalidomide and etanercept can help to avoid the potentially devastating effects of sepsis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:BACKGROUND: The aim of this study was to evaluate the therapeutic effects of thalidomide and etanercept on lipopolysaccharide(LPS)-induced sepsis in a rat model.METHODS: Thirty male Wistar Albino rats were divided into 5 groups: Control, LPS, LPS+Thalidomide, LPS+Etanercept, andLPS+Thalidomide+Etanercept.
📊
Key Findings & Data:The control group was given a 1 mL intraperitoneal (i.p.) injection of 0.9% saline solution.
💡
Conclusion & Impact:Treatment of septic animals with these agents resulted in a remarkable decrease in the selectedproinflammatory cytokines, angiogenic factors, and reactive oxygen parameters.CONCLUSION: Restoration of cytokine balance and oxidant status to normal levels following treatment with selected therapeuticagents suggests that thalidomide and etanercept can help to avoid the potentially devastating effects of sepsis.
🔬Design:Lab & Field Experiment
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

BACKGROUND: The aim of this study was to evaluate the therapeutic effects of thalidomide and etanercept on lipopolysaccharide(LPS)-induced sepsis in a rat model.METHODS: Thirty male Wistar Albino rats were divided into 5 groups: Control, LPS, LPS+Thalidomide, LPS+Etanercept, andLPS+Thalidomide+Etanercept. The control group was given a 1 mL intraperitoneal (i.p.) injection of 0.9% saline solution. For endotoxic treatment, the rats were injected with a single i.p. dose of LPS (Escherichia coli 0111:B4 (5 mg/kg). Thalidomide (0.5 mg/kg) and etanercept (1 mg/kg) were administered i.p. to the therapeutic groups. Hepatic tissue tumor necrosis factor-α (TNF-α),interleukin-6 (IL-6), intercellular adhesion molecule-1 (ICAM-1) and platelet-derived growth factor (PDGF) levels were determinedby enzyme-linked immunosorbent assay and malondialdehyde (MDA) levels and total oxidant status (TOS) were measured usingappropriate methods.RESULTS: In vivo results exhibited elevated liver tissue TNF-α, IL-6, ICAM-1, PDGF, MDA, and TOS levels in the LPS-treated animalscompared with the controls. The analysis of liver tissue supported the findings of biochemical alterations and indicated a therapeuticrole for thalidomide and etanercept. Treatment of septic animals with these agents resulted in a remarkable decrease in the selectedproinflammatory cytokines, angiogenic factors, and reactive oxygen parameters.CONCLUSION: Restoration of cytokine balance and oxidant status to normal levels following treatment with selected therapeuticagents suggests that thalidomide and etanercept can help to avoid the potentially devastating effects of sepsis.

Özet

AMAÇ: Bu çalışmada lipopolisakkaritle (LPS) indüklenmiş sıçan sepsis modelinde talidomid ve etanersept’in terapötik etkilerini değerlendirmeyi amaçladık. GEREÇ VE YÖNTEM: Otuz adet erkek Wistar Albino sıçan; Kontrol, LPS, LPS+Talidomid, LPS+Etanersept ve LPS+Talidomid+Etanersept olmak üzere beş gruba ayrıldı. Kontrol grubuna 1 mL %0.9’luk salin solüsyonu intraperitoneal (i.p.) olarak verildi. Endotoksik tedavi için sıçanlara LPS (Escherichia coli 0111: B4 (5 mg/kg), tek doz) i.p. olarak enjekte edildi. Terapötik grupları oluşturmak için talidomid (0.5 mg/kg) ve etanersept (1 mg/kg) i.p. olarak uygulandı. Hepatik doku tümör nekroz faktör-α (TNF-α), interlökin-6 (IL-6), hücreler arası adezyon molekülü-1 (ICAM-1) ve platelet-türevli büyüme faktörü (PDGF) düzeyleri ELISA yöntemiyle, malondialdehid (MDA) düzeyi ile toplam oksidan kapasitesi (TOS) uygun yöntemler kullanılarak ölçüldü. BULGULAR: In vivo sonuçlar, kontrol ile karşılaştırıldığında LPS uygulanmış hayvanlarda karaciğer TNF-α, IL-6, ICAM-1, PDGF, MDA ve TOS düzeylerinin arttığını gösterdi. Karaciğer dokularının analiziyle, biyokimyasal değişiklikler desteklendi ve talidomid ve etanersept’in terapötik rolünü kanıtladı. Septik hayvanların bu tedavi ajanlarıyla tedavi edilmesiyle seçilen proenflamatuvar sitokinler, anjiyogenik faktörler ve reaktif oksijen parametrelerinde kayda değer bir düşüş gözlendi. TARTIŞMA: Seçilen terapötik ajanların tedavisini takiben sitokin dengesinin ve oksidan durumunun normale döndürülmesi, talidomid ve etanersept’in sepsisin yıkıcı etkilerinden kaçınmaya yardımcı olabileceğini düşündürmektedir.

🔖

Cite This Article

Susam, S., Gül, H. F., İlhan, N., İlhan, N. (2022). The therapeutic effects of thalidomide and etanercept on septic rats exposed to lipopolysaccharide. Ulusal Travma ve Acil Cerrahi Dergisi, Cilt: 25 - Sayı: 2, 99–104. https://ajindex.com/articles/644252

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Nguyen HB, Smith D. Sepsis in the 21st century: recent definitions and therapeutic advances. Am J Emerg Med 2007
  2. 564–71. [CrossRef ] 2. Dickson S. Sepsis and multiple organ failure. Anaesth Inten Care Med 2009
  3. 165–8. [CrossRef ] 3. Ulloa L, Tracey KJ. The “cytokine profile”: a code for sepsis. Trends Mol Med 2005
  4. 56–63. [CrossRef ] 4. Ay BT, Avlan D, Polat A, Tamer L, Büyükavsar K, Aksöyek S. The effect of inhibition of high mobility group box-1 and tumor necrosis factor alpha on intestinal morphology and motility in rats with peritonitis. Çocuk Cerrahisi Dergisi 2008
  5. 15–24. 5. Nemzek JA, Siddiqui J, Remick DG. Development and optimization of cytokine ELISAs using commercial antibody pairs. J Immunol Methods 2001
  6. 149–57. [CrossRef ] 6. Watanabe E, Hirasawa H, Oda S, Matsuda K, Hatano M, Tokuhisa T. Extremely high interleukin-6 blood levels and outcome in the critically ill are associated with tumor necrosis factor- and interleukin-1-related genepolymorphisms. Crit Care Med 2005
  7. 89–97. [CrossRef ] 7. Rau S, Kohn B, Richter C, Fenske N, Küchenhoff H, Hartmann K, et al. Plasma interleukin-6 response is predictive for severity and mortality in canine systemic inflammatory response syndrome and sepsis. Vet Clin Pathol 2007
  8. 253–60. [CrossRef ] 8. Hildebrand F, Pape HC, Harwood P, Müller K, Hoevel P, Pütz C, et al. Role of adhesion molecule ICAM in the pathogenesis of polymicrobial sepsis. Exp Toxicol Pathol 2005
  9. 281–90. [CrossRef ] 9. Hofer S, Bopp C, Hoerner C, Plaschke K, Faden RM, Martin E, et al. Injury of the blood brain barrier and up-regulation of icam-1 in polymicrobial sepsis. J Surg Res 2008
  10. 276–81. [CrossRef ] 10. Thommen R, Humar R, Misevic G, Pepper MS, Hahn AW, John M, et al. PDGF-BB increases endothelial migration on cord movements during angiogenesis in vitro. J Cell Biochem 1997
  11. 403–13. [CrossRef ] 11. Salvemini D, Cuzzocrea S. Oxidative stress in septic shock and disseminated intravascular coagulation. Free Radic Biol Med 2002
  12. 1173–85. 12. Mishra V, Baines M, Wenstone R, Shenkin A. Markers of oxidative damage, antioxidant status and clinical outcome in critically ill patients. Ann Clin Biochem 2005
  13. 269–76. [CrossRef ] 13. Young IS, Woodside JV. Antioxidants in health and disease. J Clin Pathol 2001
  14. 176–86. [CrossRef ] 14. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951
  15. 265–75. 15. Lvovschi V, Arnaud L, Parizot C, Freund Y, Juillien